The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Demand for drugs, including weight-loss injections, is sending people to dangerous places to get their medicine. But spotting ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

With the use of these medications to help with weight loss and diabetes comes many questions about the long-term impact on ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Some patients prescribed GLP-1 drugs for weight loss have had to switch to a different medication due to changes in insurance ...

Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

If you’ve spent any time in the real world lately, chances are you’ve heard of Ozempic, Wegovy, Mounjaro or semaglutide.

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert - The Danish firm blamed the move to slash its ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...